Republicans Back Out Against Bill Aimed at Studying Cannabis to Help Veterans Suffering from Pain and PTSD
Several Senate Republican members shockingly revolted against advancing a bipartisan bill which would allow the Veterans Affairs Department to perform studies and clinical trials on the use of cannabis for treating chronic pain and post-traumatic stress disorder (PTSD).
A bipartisan bill aiming to help veterans was unfortunately crushed this past April 2023 (1). In a shocking vote, 57-42, the GOP killed Veterans Affairs Medicinal Cannabis Research Bill (S. 326) (2), just missing the 60 votes needed to move forward. Just before the vote, Senator Jon Cornyn reported that there was a Senate Republican policy lunch where a debate occurred and may have changed several Republican members support.
Critics of the bill feared over political concerns, such as the recognition that if the bill succeeded in the Senate, it would potentially be perceived as a big victory for Senator Job Tester, a Democrat who chairs the Veterans Affairs Committee and is also up for reelection in the red state of Montana (1). Going into the vote, Democrats were expecting to come out with a win for veterans because the legislation had bipartisan support in committee.
The bill was supported by 8 Republicans, which included the top Republican on the committee, Senator Jerry Moran.
Cornyn explained there are concerns about the methodology of the proposed clinical trials because (1) “this retrospective study would be done strictly through volunteers who would come forward and talk about their experience with marijuana and PTSD,” and “it depends on people to self-select and we don’t know how that would skew the results.” The senator also mentioned that members of his political party did not have “assurances” that they would be able to offer amendments to the legislation and that there were questions about whatever version of the bill that passes, would be taken up in the GOP-controlled House.
Senator Cornyn did imply that negotiations over the bill would continue and the Senate may look into picking it back up soon. He referred to the recent vote as “hitting the pause button” (1).
Not long after the vote, Senate Majority Leader Chuck Schumer, stated that it was “regrettable” about the bill being blocked and hoped there would be talks to revive it for it to pass.
References
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
